Litigation Details for JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (D.N.J. 2026)

JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (D.N.J. 2026)

Docket		Date Filed	2026-02-20
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand		Referred To
Patents	10,213,400; 10,864,181; 11,253,494; 11,986,446; 8,772,306; 9,050,302; 9,486,426
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (D.N.J. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-02-20				External link to document

Litigation summary and analysis for: JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (D.N.J. 2026)

Last updated: July 9, 2026

Litigation summary and analysis for JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (2:26-cv-01739)

Executive summary

JAZZ PHARMACEUTICALS IRELAND LIMITED sued TRIS PHARMA, INC. in the District of New Jersey under the Hatch-Waxman framework, assigned case number 2:26-cv-01739 (filed in 2026). The matter is in its early procedural stage with no enforceable merits record (claim construction, dispositive rulings, or final judgment) available from the public docket content provided in this workspace.

What is the case posture in JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (2:26-cv-01739)?

Answer: The case is newly filed and procedural history beyond the initiation is not captured in the information available here.

Docket-driven posture checkpoints

• Filing: 2026 (by docket number 2:26-cv-01739).
• Court: U.S. District Court (District of New Jersey).
• Parties: Jazz Pharmaceuticals Ireland Limited (plaintiff) v. Tris Pharma, Inc. (defendant).
• Posture: initial pleadings phase (no public merits outcomes available here).

What claims are Jazz asserting against Tris in 2:26-cv-01739?

Answer: The asserted infringement theories and specific patent list are not available in the provided material.

Patent and asserted-theory granularity missing from the accessible record

To analyze Hatch-Waxman cases at investment and litigation strategy level, the following details are required and are not present in the supplied content here:

• Asserted Orange Book patents by U.S. patent number
• Whether Jazz alleges infringement of drug substance, composition, formulation, method-of use, or manufacturing patents
• Whether the complaint is tied to a particular ANDA, 505(b)(2), or NDA reference product
• Whether Jazz asserts certifications (Paragraph I/II/III/IV) and which paragraph is at issue
• Whether the complaint includes claims under 35 U.S.C. §§ 271(e)(2) and/or 271(a)

What patents and Orange Book listings are at issue in JAZZ v. TRIS (2:26-cv-01739)?

Answer: Patent numbers and Orange Book listing identifiers are not available in the information provided.

What to extract for a litigation-grade patent map (not present here)

A complete patent estate analysis requires:

• Orange Book drug product and NDA/BLA reference ID
• Listed patents with expiration dates and PTA where applicable
• Pediatric exclusivity, 30-month stay trigger, and any forfeiture arguments
• Ownership chain (Jazz entities vs. licensing partners) and prosecution history indicators

When does Hatch-Waxman exclusivity and 30-month stay expire for this filing?

Answer: Exclusivity and stay timing cannot be computed without:

• the ANDA filing date (or applicable notice date),
• the specific paragraph certification(s),
• and whether any subsequent events altered timing (amendments, stipulations, or forfeiture motions).

Has Tris filed a Paragraph IV certification, and what does it risk?

Answer: The certification type and risk profile are not determinable from the information available here.

What would define the risk profile

Risk hinges on:

• whether this is a “first filer” triggering a longer exclusivity and earlier commercial entry window
• whether Jazz’s asserted patents include composition/formulation patents that can block “generic with different excipients”
• whether there are district-court invalidity and non-infringement trends for the same patent family

What defenses are likely raised by Tris in 2:26-cv-01739?

Answer: Defenses are not enumerated in the provided record.

Standard Hatch-Waxman defense set (cannot be attributed here)

Typical arguments include:

• non-infringement (design-around, claim construction)
• invalidity (anticipation/obviousness under §§ 102/103, indefiniteness under § 112)
• lack of statutory basis or insufficient notice (depending on certification posture)
• equitable defenses (unenforceability, prosecution history estoppel), where pleaded

How strong is the likely patent estate for Jazz’s asserted patents?

Answer: Strength cannot be evaluated because the asserted patent numbers, claim scope, and prosecution history are not supplied in the provided material.

What a strength assessment requires

A litigation-grade strength view depends on:

• claim charts tied to the exact formulation or method described in the patents
• how the patents have been construed in related cases
• whether the patent family has survived PTAB challenges or prior district outcomes
• whether the asserted claims are early or late in the life cycle (older foundational vs. later continuation claims)

What is the procedural timeline for 2:26-cv-01739 (events, motions, deadlines)?

Answer: A motion-by-motion timeline cannot be produced from the supplied information.

Timeline artifacts needed for analysis

A complete timeline includes:

• complaint filing date and service date
• answer or motion to dismiss dates
• Rule 26 scheduling order date
• claim construction deadlines
• summary judgment dates
• any stipulation for stay termination or dismissal

Did the case settle, and what are the settlement terms?

Answer: Settlement status and terms are not available in the provided material.

What settlement documents would change commercially

Settlement affects:

• earliest permitted launch date (workable date)
• scope carve-outs (skinny label, design-around requirements)
• cross-licenses or covenants not to sue
• payment structure and whether it is linked to milestone or sales-based triggers

What is the FDA regulatory status relevant to this litigation?

Answer: The FDA status (ANDA/NDA number, application type, approval, tentative approval, or label posture) is not provided.

What to determine for decision-grade impact

FDA/regulatory impact requires:

• ANDA submission reference (505(b)(2) vs. ANDA)
• tentative approval date, if any
• labeling and exclusivity conditions
• whether there is a pediatric exclusivity or 180-day exclusivity risk overlay

How does this dispute compare with other recent Jazz vs. generic or Tris-related Hatch-Waxman cases?

Answer: No comparative dataset can be constructed because the asserted product and patent family are not identified here.

Comparison framework (not executable without the drug/patent identity)

• commonality of patent families across Jazz’s portfolio
• frequency of district-court outcomes for those patents
• whether Tris repeats the same product strategy across defendants

Commercial entry risk: what generic launch scenarios are blocked or enabled?

Answer: Launch scenarios cannot be evaluated without the drug product identity and the asserted patent list.

Scenario mapping depends on

• whether patents include formulation/composition barriers (excipient-based design)
• whether the asserted patents are method-of-use (label carve-outs may be needed)
• whether the case targets a key delivery system or dosage form
• whether a settlement or early court ruling narrows the asserted claims

Jurisdiction and enforcement scope: where can Jazz enforce?

Answer: The case is in the U.S. District Court for the District of New Jersey; geographic enforcement is national for Hatch-Waxman injunctions, but the available content does not include injunctive rulings or final scope.

Key Takeaways

• Case identification is clear: JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC., 2:26-cv-01739 in the District of New Jersey.
• The actionable litigation record (asserted patents, FDA application linkage, certification type, defenses, and procedural milestones) is not present in the information available here.
• Without the complaint’s patent list and product linkage, exclusivity timing, likely strength, and commercial entry risk cannot be quantified.

FAQs

1. What is a Hatch-Waxman case number like 2:26-cv-01739 tied to?
   It ties to a specific federal district-court docket in the filing jurisdiction; Hatch-Waxman disputes typically map to an ANDA/505(b)(2) notice and Orange Book patent list, but the underlying linkage is not available in the provided content.

2. How do you calculate the 30-month stay in a Paragraph IV Hatch-Waxman case?
   It depends on the ANDA notice date and certification context; the necessary dates and certification details are not available in the provided material.

3. Does a Jazz v. generic case always involve Paragraph IV certifications?
   Most Hatch-Waxman infringement suits do, but the certification paragraph is not specified in the provided information.

4. Can generic launch happen during litigation?
   It can be blocked or delayed by the court’s rulings and any statutory stays; the procedural status and any injunctions are not provided here.

5. What information is essential to assess patent strength in district-court Hatch-Waxman suits?
   The asserted U.S. patent numbers, claim language, the accused product’s parameters, and the FDA application linkage; none of those specifics are included in the material provided here.

---

References

1. U.S. District Court for the District of New Jersey, Case No. 2:26-cv-01739, JAZZ PHARMACEUTICALS IRELAND LIMITED v. TRIS PHARMA, INC. (2026).